Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin in Relapsed/Refractory Mantle Cell or Diffuse Large Cell Lymphoma
NCT00383565Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Sep 2006
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romidepsin in mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL), sponsored by National Cancer Institute. Primary endpoint: Overall Objective Response Rate (Complete Response [CR] and Partial Response [PR]) at 24 weeks. Started Sep 2006; status: terminated.
02
Drugs
romidepsin
03
Conditions
mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00383565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00383565.